TY - JOUR
T1 - Reduction of morning stiffness and improvement in physical function in fibromyalgia syndrome patients treated sublingually with low doses of human interferon-α
AU - Russell, I. Jon
AU - Michalek, Joel E.
AU - Kang, Yoon Kyoo
AU - Richards, Alan B.
PY - 1999
Y1 - 1999
N2 - One hundred and twelve fibromyalgia syndrome (FMS) patients were randomized into one of four demographically similar groups (n = 28/group). Sequential primary FMS patient volunteers were to receive daily sublingual placebo or interferon-α (IFN-α) at 15, 50, or 150 IU. After a screening evaluation, analgesic or sedative hypnotic medications were withdrawn. Two weeks later, daily IFN-α or placebo was initiated with follow-up evaluations at 2-week intervals ending with week 6. One primary, three secondary, and seven tertiary variables were assessed. Study outcome was based on improvement in the tender point index (TPI). The TPI did not improve with any IFN-α dose. However, significant improvement was seen in morning stiffness and in physical function with the 50 IU IFN-α (p < 0.01). None of the other outcome means changed significantly and no adverse events were attributable to IFN-α therapy.
AB - One hundred and twelve fibromyalgia syndrome (FMS) patients were randomized into one of four demographically similar groups (n = 28/group). Sequential primary FMS patient volunteers were to receive daily sublingual placebo or interferon-α (IFN-α) at 15, 50, or 150 IU. After a screening evaluation, analgesic or sedative hypnotic medications were withdrawn. Two weeks later, daily IFN-α or placebo was initiated with follow-up evaluations at 2-week intervals ending with week 6. One primary, three secondary, and seven tertiary variables were assessed. Study outcome was based on improvement in the tender point index (TPI). The TPI did not improve with any IFN-α dose. However, significant improvement was seen in morning stiffness and in physical function with the 50 IU IFN-α (p < 0.01). None of the other outcome means changed significantly and no adverse events were attributable to IFN-α therapy.
UR - http://www.scopus.com/inward/record.url?scp=0032873031&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032873031&partnerID=8YFLogxK
U2 - 10.1089/107999099313514
DO - 10.1089/107999099313514
M3 - Article
C2 - 10476944
AN - SCOPUS:0032873031
SN - 1079-9907
VL - 19
SP - 961
EP - 968
JO - Journal of Interferon and Cytokine Research
JF - Journal of Interferon and Cytokine Research
IS - 8
ER -